↓ Skip to main content

Dove Medical Press

Article Metrics

Giant-cell tumor of bone: treatment options and role of denosumab

Overview of attention for article published in Biologics: Targets & Therapy, July 2015
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#45 of 130)
  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
44 Dimensions

Readers on

mendeley
83 Mendeley
Title
Giant-cell tumor of bone: treatment options and role of denosumab
Published in
Biologics: Targets & Therapy, July 2015
DOI 10.2147/btt.s57359
Pubmed ID
Authors

Sant P. Chawla, Neal Chawla, Arun Singh

Abstract

Giant-cell tumor of bone is a rare, locally aggressive tumor that typically occurs in the bones of skeletally mature young adults in their second to fourth decades. Traditionally, surgery has been the mainstay of therapy for this disease, but the disease can recur even with optimal procedures. Furthermore, it may occur in locations where a surgical approach would be morbid. The maturation of the understanding of the role of the receptor activator of nuclear factor-κB ligand (RANKL) in the pathophysiology of giant-cell tumor of bone has led to the use of denosumab, a monoclonal antibody against RANKL, in this disease. In 2013, the US Food and Drug Administration approved denosumab for use in patients with recurrent/unresectable/metastatic giant-cell tumor of bone or for patients in whom surgery would be morbid.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 83 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 17 20%
Student > Ph. D. Student 11 13%
Researcher 9 11%
Student > Bachelor 6 7%
Student > Master 6 7%
Other 17 20%
Unknown 17 20%
Readers by discipline Count As %
Medicine and Dentistry 48 58%
Agricultural and Biological Sciences 3 4%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Arts and Humanities 1 1%
Nursing and Health Professions 1 1%
Other 6 7%
Unknown 21 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 July 2015.
All research outputs
#2,493,070
of 5,402,352 outputs
Outputs from Biologics: Targets & Therapy
#45
of 130 outputs
Outputs of similar age
#84,950
of 186,514 outputs
Outputs of similar age from Biologics: Targets & Therapy
#3
of 5 outputs
Altmetric has tracked 5,402,352 research outputs across all sources so far. This one has received more attention than most of these and is in the 51st percentile.
So far Altmetric has tracked 130 research outputs from this source. They receive a mean Attention Score of 2.2. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 186,514 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.